Immunotherapy
Conversion of non-responsive into responsive patients with development of new combination therapies
-
Secretary
Concetta Quintarelli - Paola Nisticò
OPBG ROMA - IRE ROMA
-
Clinical Coordinator
Emilio Bria
GEMELLI ROMA
-
Pre Clinical Coordinator
Vincenzo Russo
OSR MILANO
-
CAR-T Clinical Coordinator
Franco Locatelli
OPBG ROMA
-
Pre Clinical Coordinator CAR-T
Chiara Bonini
OSR MILANO
The Immunotherapy Working Group deals with identifying highly predictive biomarkers of response to new immunotherapeutic approaches to identify at an early stage those patients who are likely to benefit from treatment. In this way, it is possible to avoid delivering therapies that can cause side effects while offering no clinical benefit.
The work of the WG, coordinated by Concetta Quintarelli (Bambino Gesù Children’s Hospital in Rome) and Paola Nisticò (IRE Rome), is focused on converting non-responsive patients into responsive ones through the development of new combined therapies.
Immunotherapy is an innovative therapeutic approach that uses the patient’s immune system to recognize and eliminate neoplasia as though an infection. This is achieved by activating the patient’s immune system to recognise and eliminate cancer cells that are often hidden from the immune system. Therefore, to make them recognizable, substances are infused into the patient to activate the immune system, specifically, antibodies and immunoglobulin that selectively recognize cancer cells. They form a bridge between cancer cells and the immune system and activate the latter to identify and eliminate the former.
Even more innovative strategies involve genetically modifying the patient’s lymphocyte T-cells in the laboratory to induce the presence of specific receptors in them to recognize an antigen expressed on the cancer cell. The receptors – chimeric antigen receptors- are usually inserted by viral vectors into the T cell. Once exposed on its membrane, they circulate like soldiers in the patient and can recognize the metastatic sites of some neoplasm.
The focus for the future will be on creating specific, targeted therapies for each patient, which can only be achieved through the work of a network like ACC, which brings together clinical specialties and researchers from different fields. The characterization of each patient will enable us to determine the correct therapy, thereby increasing benefits and at the same time reducing toxicities.
Team
- Pre-Clinics
- Clinicians
-
OPBG ROMA
Concetta Quintarelli
-
IRE ROMA
Paola Nisticò
-
CRO AVIANO
Stefania Zanussi
-
ONCOLOGICO BARI
Stefania Tommasi
-
IRCC CANDIOLO
Dario Sangiolo
-
HUMANITAS
Paola Allavena
-
INT MILANO
Andrea Anichini
-
BESTA MILANO
Serena Pellegatta
-
CSS S.G. ROTONDO
Paolo Graziano
-
IRCCS GEMELLI ROMA
Tobias Haas
-
CSS S.G. ROTONDO
Vincenzo Giambra
-
IRST MELDOLA
Massimiliano Mazza
-
INT PASCALE
Mariaelena Capone
-
IRCCS GASLINI
Marina Podestà
-
AUSL-IRCCS
Valentina Sancisi
-
HUMANITAS
Barbara Bottazzi
-
IEO MILANO
Luigi Nezi
-
IRST MELDOLA
Marcella Tazzari
-
IOV PADOVA
Antonio Rosato
-
OSR MILANO
Vincenzo Russo
-
INT MILANO
Giancarlo Pruneri
-
OSP. POL. S. MARTINO GENOVA
Gabriella Pietra
-
OSR MILANO
Chiara Bonini
-
SAN MATTEO
Patrizia Morbini
-
IRCCS CANDIOLO
Vanesa Gregorc
-
IRST MELDOLA
Massimo Guidoboni
-
PASCALE NAPOLI
Paolo Ascierto
-
CRO AVIANO
Lucia Fratino
-
ONCOLOGICO BARI
Domenico Galetta
-
IRCC CANDIOLO
Fabrizio Carnevale Schianca
-
IOV PADOVA
Maria Vittoria Dieci
-
IEO MILANO
Giuseppe Curigliano
-
HUMANITAS
Paolo Zucali
-
INT MILANO
Massimo Di Nicola
-
IRCCS GEMELLI ROMA
Giampaolo Tortora
-
IRCCS IRE
Virginia Ferraresi
-
IRCCS GASLINI
Stefano Giardino
-
IDI ROMA
Cristiana Di Rocco
-
CSS S.G. ROTONDO
Concetta Di Micco
-
HUMANITAS
Armando Santoro
-
IRCCS-CROB
Giovanni Bozza
-
OPBG-ROMA
Franco Locatelli
-
GEMELLI ROMA
Emilio Bria
-
SAN MATTEO
Francesco Augustoni
-
OSP. POL. S. MARTINO GENOVA
Raffaele De Palma